Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Vervita K"'
Autor:
Dafni, U., Soo, R. A., Peters, S., Tsourti, Z., Zygoura, P., Vervita, K., Han, J-Y, De Castro, J., Coate, L., Fruh, M., Hashemi, S. M. S., Nadal, E., Carcereny, E., Sala, M. A., Bernabe, R., Provencio, M., Cuffe, S., Roschitzki-Voser, H., Ruepp, B., Rosell, R., Stahel, R. A.
Background: The ETOP 10-16 BOOSTER trial failed to demonstrate a progression-free survival (PFS) benefit for adding bevacizumab to osimertinib in second line. An exploratory subgroup analysis, however, suggested a PFS benefit of the combination in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2636::801bc88be8f25f3fa5e318e970392eab
https://hdl.handle.net/10668/22216
https://hdl.handle.net/10668/22216
Autor:
Ruschoff, J.H., Haberecker, M., Tsourti, Z., Nackaerts, K., Perrot, M. de, Brcic, L., Nadal, E., Tsimpoukis, S., Gray, S.G., Ampollini, L., Aerts, J.G., Felley-Bosco, E., Kirschner, M.B., Monkhorst, K., Weynand, B., Bavaghar-Zaeimi, F., Samarzija, M., Llatjos, R., Finn, S.P., Silini, E., Thusen, J. von der, Marti, N., Vervita, K., Kammler, R., Peters, S., Stahel, R.A., Baas, P., Opitz, I., Consortium, E.M.
Publikováno v:
Modern Pathology. SPRINGERNATURE
Modern Pathology
Modern Pathology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::004cfab0fe7d7d9e416d8f3725b7d02d
https://doi.org/10.1038/s41379-022-01170-z
https://doi.org/10.1038/s41379-022-01170-z
Autor:
Dafni, U., Soo, R. A., Peters, S., Tsourti, Z., Vervita, K., Han, J-Y., De Castro, J., Coate, L., Frueh, M., Hashemi, S. M. S., Nadal, E., Carcereny, E., Sala Gonzalez, M. Angeles, Bernabe Caro, R., Provencio Pulla, M., Cuffe, S., Ruepp, B., Roschitzki-Voser, H., Rosell, R., Stahel, R. A.
Publikováno v:
Annals of Oncology, 33, S46-S47. Oxford University Press
Annals of Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Dafni, U, Soo, R A, Peters, S, Tsourti, Z, Vervita, K, Han, J-Y, De Castro, J, Coate, L, Frueh, M, Hashemi, S M S, Nadal, E, Carcereny, E, Sala Gonzalez, M A, Bernabe Caro, R, Provencio Pulla, M, Cuffe, S, Ruepp, B, Roschitzki-Voser, H, Rosell, R & Stahel, R A 2022, ' Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis ', Annals of Oncology, vol. 33, pp. S46-S47 . https://doi.org/10.1016/j.annonc.2022.02.041
Annals of Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Dafni, U, Soo, R A, Peters, S, Tsourti, Z, Vervita, K, Han, J-Y, De Castro, J, Coate, L, Frueh, M, Hashemi, S M S, Nadal, E, Carcereny, E, Sala Gonzalez, M A, Bernabe Caro, R, Provencio Pulla, M, Cuffe, S, Ruepp, B, Roschitzki-Voser, H, Rosell, R & Stahel, R A 2022, ' Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis ', Annals of Oncology, vol. 33, pp. S46-S47 . https://doi.org/10.1016/j.annonc.2022.02.041
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::64418512fae0d484e5ce8ebd614883eb
https://research.vumc.nl/en/publications/d5c9a352-1e46-4991-8903-14041df7240f
https://research.vumc.nl/en/publications/d5c9a352-1e46-4991-8903-14041df7240f
Autor:
Dafni, U, Soo, R A, Peters, S, Tsourti, Z, Zygoura, P, Vervita, K, Han, J-Y, De Castro, J, Coate, L, Früh, M, Hashemi, S M S, Nadal, E, Carcereny, E, Sala, M A, Bernabé, R, Provencio, M, Cuffe, S, Roschitzki-Voser, H, Ruepp, B, Rosell, R, Stahel, R A
Publikováno v:
Dafni, U; Soo, R A; Peters, S; Tsourti, Z; Zygoura, P; Vervita, K; Han, J-Y; De Castro, J; Coate, L; Früh, M; Hashemi, S M S; Nadal, E; Carcereny, E; Sala, M A; Bernabé, R; Provencio, M; Cuffe, S; Roschitzki-Voser, H; Ruepp, B; Rosell, R; ... (2022). Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis. ESMO open, 7(3), p. 100507. Elsevier 10.1016/j.esmoop.2022.100507
Dafni, U, Soo, R A, Peters, S, Tsourti, Z, Zygoura, P, Vervita, K, Han, J Y, de Castro, J, Coate, L, Früh, M, Hashemi, S M S, Nadal, E, Carcereny, E, Sala, M A, Bernabé, R, Provencio, M, Cuffe, S, Roschitzki-Voser, H, Ruepp, B, Rosell, R & Stahel, R A 2022, ' Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis ', ESMO OPEN, vol. 7, no. 3, 100507 . https://doi.org/10.1016/j.esmoop.2022.100507
ESMO OPEN, 7(3):100507. BMJ Publishing Group
Dafni, U, Soo, R A, Peters, S, Tsourti, Z, Zygoura, P, Vervita, K, Han, J Y, de Castro, J, Coate, L, Früh, M, Hashemi, S M S, Nadal, E, Carcereny, E, Sala, M A, Bernabé, R, Provencio, M, Cuffe, S, Roschitzki-Voser, H, Ruepp, B, Rosell, R & Stahel, R A 2022, ' Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis ', ESMO OPEN, vol. 7, no. 3, 100507 . https://doi.org/10.1016/j.esmoop.2022.100507
ESMO OPEN, 7(3):100507. BMJ Publishing Group
BACKGROUND The ETOP 10-16 BOOSTER trial failed to demonstrate a progression-free survival (PFS) benefit for adding bevacizumab to osimertinib in second line. An exploratory subgroup analysis, however, suggested a PFS benefit of the combination in pat
Background: Concurrent chemotherapy and thoracic radiotherapy followed by prophylactic cranial irradiation (PCI) is the standard treatment in limited-disease small-cell lung cancer (ID-SCLC), with 5-year overall survival (OS) of only 25% to 33%. Pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::4f477ab2a867db22fd42bde94f4e2ffb
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3033920
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3033920
Background: Therapeutic cancer vaccination is an area of interest, even though promising efficacy has not been demonstrated so far. Design: A systematic review and meta-analysis was conducted to evaluate vaccines’ efficacy on breast cancer (BC) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::eeafb416a2c58a1b37dd3377277e54be
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3076359
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3076359
This network meta-analysis (NMA), based on 12 phase-III studies with 9,236 metastatic NSCLC patients, aims to compare the efficacy of treatments including at least one immune-checkpoint inhibitor (ICI) with or without chemotherapy, as frontline thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::e2737b064a5f71f3c982c0357789f90f
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3077408
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3077408
PURPOSE To better understand the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) and the ASCO Value Framework Net Health Benefit score version 2 (ASCO-NHB v2), ESMO and ASCO collaborated to evalu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::6e93e5dfb475b6a33c968bb65a66735b
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3077424
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3077424